A detailed history of Tower Research Capital LLC (Trc) transactions in In8 Bio, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 13,189 shares of INAB stock, worth $3,297. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,189
Previous 3,785 248.45%
Holding current value
$3,297
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.27 - $0.88 $2,539 - $8,275
9,404 Added 248.45%
13,189 $3,000
Q2 2024

Aug 13, 2024

SELL
$0.85 - $1.68 $6,040 - $11,938
-7,106 Reduced 65.25%
3,785 $3,000
Q1 2024

May 15, 2024

BUY
$0.95 - $1.69 $4,562 - $8,117
4,803 Added 78.89%
10,891 $12,000
Q4 2023

Feb 13, 2024

SELL
$0.69 - $2.34 $3,895 - $13,211
-5,646 Reduced 48.12%
6,088 $8,000
Q3 2023

Nov 14, 2023

BUY
$0.92 - $1.74 $4,563 - $8,630
4,960 Added 73.22%
11,734 $12,000
Q2 2023

Aug 14, 2023

BUY
$1.05 - $3.24 $1,984 - $6,123
1,890 Added 38.7%
6,774 $10,000
Q1 2023

May 09, 2023

SELL
$1.17 - $2.83 $2,091 - $5,060
-1,788 Reduced 26.8%
4,884 $6,000
Q4 2022

Feb 10, 2023

BUY
$1.39 - $2.47 $6,742 - $11,981
4,851 Added 266.39%
6,672 $15,000
Q3 2022

Nov 10, 2022

SELL
$1.77 - $2.89 $638 - $1,043
-361 Reduced 16.54%
1,821 $4,000
Q2 2022

Aug 15, 2022

SELL
$2.02 - $4.68 $2,450 - $5,676
-1,213 Reduced 35.73%
2,182 $5,000
Q1 2022

May 12, 2022

BUY
$2.76 - $4.6 $604 - $1,007
219 Added 6.9%
3,395 $11,000
Q4 2021

Feb 14, 2022

BUY
$4.39 - $8.55 $1,216 - $2,368
277 Added 9.56%
3,176 $14,000
Q3 2021

Nov 15, 2021

BUY
$6.71 - $10.0 $19,452 - $28,990
2,899 New
2,899 $20,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.13M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.